Replimune Group Inc (REPL)

$4.73 +0.08 (1.72%)
Market Cap 369.21M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.14
Volume 2,504,100
Avg Vol 9,334,168
Day's Range N/A - N/A
Shares Out 78.06M
Stochastic %K 97%
Beta 0.42
Analysts Hold
Price Target $4.67

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
07TX
07TX Oct. 2 at 8:28 PM
$REPL nice day. Ready to bust $5 tomorrow
1 · Reply
DARKP00L
DARKP00L Oct. 2 at 4:08 PM
$REPL this stock is attracting a lot of interest. Be prepared for possible changes!
0 · Reply
07TX
07TX Oct. 2 at 1:50 PM
$REPL time to close that gap
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 2:17 AM
$REPL: Unusual Options Activity Alerted CALL flow observed 1346x contracts at Strike price of $6 Exp on 10/17/2025 with Premium of $34K and showing BULLISH Sentiment
0 · Reply
Nikkosi
Nikkosi Oct. 1 at 7:43 PM
$REPL Why is this not under $3??
0 · Reply
Cliff_Huxtable
Cliff_Huxtable Oct. 1 at 4:10 PM
$REPL This is a tragedy. It makes me sick to my stomach.
0 · Reply
adamoliveran
adamoliveran Sep. 30 at 6:01 PM
$REPL Not giving up on this for even one second. The treatment is there and truth will overcome !!!
0 · Reply
Millaros
Millaros Sep. 30 at 10:47 AM
$OTLK wondering if this will start filling the gap like $REPL did post-CRL at beginning of August. (Based on nothing just looks similar)
2 · Reply
highnihilism
highnihilism Sep. 30 at 7:45 AM
$CHRW C.H. Robinson: 208 trades, $323K vs $772K avg (0.42x). $301K calls / $23K puts. 100% single-leg. $REPL Replimune: 666 trades, $324K vs $711K avg (0.46x). $300K calls / $24K puts. 92% single-leg. $HTZ Hertz: 1,088 trades, $479K vs $2.29M avg (0.21x). $298K calls / $181K puts. 91% single-leg. $CLX Clorox: 528 trades, $757K vs $3.29M avg (0.23x). $296K calls / $461K puts. 21% single-leg.
0 · Reply
Halbalidiya
Halbalidiya Sep. 29 at 10:44 PM
$REPL shorting this exit liquidity to 0!!🤡🖕
0 · Reply
Latest News on REPL
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 21, 2025, 7:40 AM EDT - 13 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 16 days ago

Replimune Provides Update Following Type A Meeting with FDA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 13, 2025, 10:10 AM EDT - 21 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 5, 2025, 6:54 PM EDT - 4 weeks ago

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 2, 2025, 9:46 PM EDT - 4 weeks ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

Replimune Announces Type A Meeting Scheduled with FDA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Aug 13, 2025, 4:39 PM EDT - 7 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Aug 13, 2025, 3:26 PM EDT - 7 weeks ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 10:08 AM EDT - 2 months ago

Replimune Group: The Prospects For FDA Approval After Rejection

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 2 months ago

Why Is Replimune Stock Trading Lower On Monday?

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Aug 1, 2025, 10:51 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 2 months ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 2 months ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 2 months ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 24, 2025, 8:07 AM EDT - 2 months ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 2:56 PM EDT - 2 months ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 22, 2025, 11:03 AM EDT - 2 months ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:01 PM EDT - 3 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2025, 10:00 AM EDT - 4 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 4 months ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 11:19 AM EDT - 4 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

May 22, 2025, 7:00 AM EDT - 4 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

May 16, 2025, 8:00 AM EDT - 5 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 4:01 PM EDT - 5 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 5 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

COYA

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Apr 28, 2025, 3:26 PM EDT - 5 months ago

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Replimune: A Misunderstood Contender In Oncolytics

Feb 12, 2025, 4:21 PM EST - 8 months ago

Replimune: A Misunderstood Contender In Oncolytics

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 12, 2025, 8:00 AM EST - 8 months ago

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 8:00 AM EST - 10 months ago

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Nov 29, 2024, 4:12 AM EST - 11 months ago

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune Announces Pricing of Upsized Public Offering

Nov 25, 2024, 11:55 PM EST - 11 months ago

Replimune Announces Pricing of Upsized Public Offering

Replimune Announces Proposed Public Offering

Nov 25, 2024, 7:09 AM EST - 11 months ago

Replimune Announces Proposed Public Offering

07TX
07TX Oct. 2 at 8:28 PM
$REPL nice day. Ready to bust $5 tomorrow
1 · Reply
DARKP00L
DARKP00L Oct. 2 at 4:08 PM
$REPL this stock is attracting a lot of interest. Be prepared for possible changes!
0 · Reply
07TX
07TX Oct. 2 at 1:50 PM
$REPL time to close that gap
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 2:17 AM
$REPL: Unusual Options Activity Alerted CALL flow observed 1346x contracts at Strike price of $6 Exp on 10/17/2025 with Premium of $34K and showing BULLISH Sentiment
0 · Reply
Nikkosi
Nikkosi Oct. 1 at 7:43 PM
$REPL Why is this not under $3??
0 · Reply
Cliff_Huxtable
Cliff_Huxtable Oct. 1 at 4:10 PM
$REPL This is a tragedy. It makes me sick to my stomach.
0 · Reply
adamoliveran
adamoliveran Sep. 30 at 6:01 PM
$REPL Not giving up on this for even one second. The treatment is there and truth will overcome !!!
0 · Reply
Millaros
Millaros Sep. 30 at 10:47 AM
$OTLK wondering if this will start filling the gap like $REPL did post-CRL at beginning of August. (Based on nothing just looks similar)
2 · Reply
highnihilism
highnihilism Sep. 30 at 7:45 AM
$CHRW C.H. Robinson: 208 trades, $323K vs $772K avg (0.42x). $301K calls / $23K puts. 100% single-leg. $REPL Replimune: 666 trades, $324K vs $711K avg (0.46x). $300K calls / $24K puts. 92% single-leg. $HTZ Hertz: 1,088 trades, $479K vs $2.29M avg (0.21x). $298K calls / $181K puts. 91% single-leg. $CLX Clorox: 528 trades, $757K vs $3.29M avg (0.23x). $296K calls / $461K puts. 21% single-leg.
0 · Reply
Halbalidiya
Halbalidiya Sep. 29 at 10:44 PM
$REPL shorting this exit liquidity to 0!!🤡🖕
0 · Reply
Halbalidiya
Halbalidiya Sep. 29 at 8:57 PM
$IOBT disgusting, disgraceful rug pull by the corrupt deep state tutes. This will be done to $REPL as well. They will run the news cycle so you think you have a moon shot and peg the price higher and then rip off the table cloth. Retial IS USED AS EXIT LIQUIDITY. WE MUST UNITE AND STOP FALLING INTO THE TRAPS THEY LAY FOR US. SHORTING THESE TO 0
2 · Reply
TraderJoe65
TraderJoe65 Sep. 29 at 7:24 PM
$REPL How is this possible? 4 points less improvement over Placebo vs the competition cause a 90% collapse of company value . ill take the chance this recovers at some point.
0 · Reply
Evagaminska
Evagaminska Sep. 29 at 7:09 PM
$MLTX Remember $REPL crooks got so carried away with their algos that stock traded -110% Then they corrected it
0 · Reply
Doplrshift
Doplrshift Sep. 29 at 6:49 PM
$REPL took my 10% and sold it all
1 · Reply
JMG2000
JMG2000 Sep. 29 at 6:26 PM
$REPL News?
0 · Reply
ignoreo
ignoreo Sep. 29 at 3:46 PM
$REPL this should have traded down ~20% today imo
0 · Reply
Jecob_Edwards
Jecob_Edwards Sep. 29 at 2:48 PM
$REPL RP1 has shown real promise, and patients know the difference it can make. The FDA’s decision is not rejection but delay, and the urgent challenge is making sure access comes sooner, because every day matters for those fighting advanced melanoma.
1 · Reply
ignoreo
ignoreo Sep. 29 at 2:48 AM
is $IOBT more like $PGEN or $REPL?
0 · Reply
StockKarate
StockKarate Sep. 28 at 5:39 PM
Love seeing the green on this graph. Looking good !! Keep it going $REPL show them what you got (RP1)
0 · Reply
Doplrshift
Doplrshift Sep. 26 at 6:09 PM
$REPL someone did a massive share dump
0 · Reply
ShadowBull3745
ShadowBull3745 Sep. 26 at 5:11 PM
$REPL 😅This is not going to be approved any time soon.
0 · Reply
Doplrshift
Doplrshift Sep. 26 at 2:32 PM
$REPL this needs to get to $4.20 for a breakout
0 · Reply